Status:
COMPLETED
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Biogen
Conditions:
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Detailed Description
Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followe...
Eligibility Criteria
Inclusion
- Conformed diagnosis of follicular lymphoma, grades 1,2 or 3
- No prior chemotherapy
- No prior monoclonal antibody therapy
- Bulky or symptomatic disease, stage II-IV
- Performance status 0-2
Exclusion
- Impaired bone marrow reserve
- Presence of CNS lymphoma
- Serious nonmalignant disease or active infection
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00177554
Start Date
November 1 2003
End Date
May 1 2007
Last Update
May 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Cancer Centers
Pittsburgh, Pennsylvania, United States, 15232